𝔖 Bobbio Scriptorium
✦   LIBER   ✦

PP 25 Preclinical efficacy of a dual PI3K-mTOR inhibitor, BEZ235 in triple negative breast cancer

✍ Scribed by N. Dey; H. Wu; Y. Sun; P. De; B. Leyland-Jones

Book ID
117661773
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
56 KB
Volume
47
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The efficacy of a novel, dual PI3K/mTOR
The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer
✍ Niranjan Awasthi; Peter L. Yen; Margaret A. Schwarz; Roderich E. Schwarz πŸ“‚ Article πŸ“… 2012 πŸ› John Wiley and Sons 🌐 English βš– 419 KB

## Abstract Gemcitabine has limited clinical benefits for pancreatic ductal adenocarcinoma (PDAC). The phosphatidylinositol‐3‐kinase (PI3K)/AKT and mammalian target of rapamycin (mTOR) signaling pathways are frequently dysregulated in PDAC. We investigated the effects of NVP‐BEZ235, a novel dual PI